Validated HPLC–MS–MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma—pharmacokinetic study

被引:0
作者
V. Bořek-Dohalský
J. Huclová
B. Barrett
B. Němec
I. Ulč
I. Jelínek
机构
[1] CEPHA s.r.o. Plzen,Bioanalytical Laboratory
[2] Charles University Prague,Department of Analytical Chemistry
来源
Analytical and Bioanalytical Chemistry | 2006年 / 386卷
关键词
Atorvastatin; HPLC; MS; Plasma; Pharmacokinetic study;
D O I
暂无
中图分类号
学科分类号
摘要
Cholesterol-reducing statin drugs are the most frequently prescribed agents for reducing morbidity and mortality related to coronary heart disease. In this publication a validated, highly sensitive, and selective isocratic HPLC method is reported for quantitative determination of the major statin drug atorvastatin (ATV) and its metabolite 2-hydroxyatorvastatin (HATV). Detection was performed with an electrospray ionization triple-quadrupole mass spectrometer equipped with an ESI interface operating in positive-ionization mode. Multiple reaction monitoring (MRM) was used for MS–MS detection. The calibration plot was linear in the concentration range 0.10–40.00 ng mL−1 for both ATV and HATV. Inter-day and intra-day precision and accuracy of the proposed method were characterized by measurement of relative standard deviation (RSD) and percentage deviation, respectively; both were less than 8% for both analytes. The limit of quantitation was 0.02 ng mL−1 for ATV and 0.07 ng mL−1 for HATV. The method was used for pharmacokinetic study of ATV and HATV. Pharmacokinetic data for all analytes are also reported.
引用
收藏
页码:275 / 285
页数:10
相关论文
共 35 条
[1]  
Lea AP(1997)undefined Drugs 53 828-847
[2]  
McTavish D(1998)undefined Clin Pharmacol Ther 64 58-65
[3]  
Kantola T(1999)undefined Clin Pharmacol Ther 66 118-127
[4]  
Kivistö KT(2003)undefined J Pharm Biomed Anal 33 1017-1023
[5]  
Neuvonen PJ(2004)undefined Crit Rev Anal Chem 34 1-7
[6]  
Lilja JJ(2001)undefined Anal Chem 73 582-588
[7]  
Kivistö KT(1999)undefined Rapid Commun Mass Spectrom 13 1003-1015
[8]  
Neuvonen PJ(1999)undefined J Am Soc Mass Spectrom 10 55-66
[9]  
Ertuk S(1996)undefined J Clin Pharmacol 36 728-731
[10]  
Aktas ES(1995)undefined J Clin Pharmacol 35 990-994